Medtronic's cardiovascular sales rise 10.8% to $3.44 bln CEO emphasizes on cardiology and neuroscience M&A CFO confirms diabetes business to go public in 2026 Nov 18 (Reuters) - Medtronic (MDT.N), ...

CLARION, Iowa (KTTC) – It was a historic moment for Iowa Specialty Hospital as the organization becomes the first Iowa hospital to use improved pill cameras in real-time. These are pill-like ...

While there is no cure for Parkinson’s disease, there’s now a better way to control its involuntary muscle movements. In February, the FDA approved Medtronic’s BrainSense adaptive deep brain ...

When Elliott Management quietly became one of Medtronic's largest investors recently, it wasn't just another Wall Street transaction. It was the beginning of a high-stakes intervention in a company ...

Medtronic MDT-0.62%decrease; red down pointing triangle is making changes to its board after Elliott Investment Management became one of its largest shareholders. The activist investor and the medical ...

Medtronic (NYSE:MDT) will add two new directors and establish additional committees after Elliott Investment Management emerged as one of its largest shareholders. The move was first reported by the ...

Medtronic is separating out its lower-margin diabetes care segment. It's also pouncing on a massive opportunity in robotic-assisted surgery. The healthcare leader has a terrific dividend-growth track ...

On Wednesday, the Centers for Medicare & Medicaid Services (CMS) proposed a significant step toward broader adoption of renal denervation (RDN) by offering coverage for both radiofrequency (rfRDN) and ...

Deal Overview On May 21, 2025, Medtronic plc (NYSE: MDT; $87.44, Market Capitalization: $112.1 billion), a global leader in medical technology, announced its intent to spin off its Diabetes business ...

In a surprise move, Medtronic plans to spin off its diabetes business. This is Medtronic's smallest business, but also its fastest-growing one. The new entity could be attractive to more ...

Medtronic’s decision to spin out its diabetes division into a separate entity marks a major shift — one that allows the medical device giant to shed a lower-margin, consumer-facing business, while ...

Upgrading Medtronic to 'Strong Buy' with a $104 fair value, driven by the diabetes business spin-off catalyst. Divesting diabetes enables Medtronic to focus on core cardiac and surgical markets, ...